[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 95 of about 95
1. Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, Pasternack GR, Yeo CJ: Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol; 2007 Dec;20(12):1238-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia.
  • Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers.
  • The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Biomarkers, Tumor / analysis. Gene Expression. Humans. Immunoblotting. Immunohistochemistry. Phosphoproteins / biosynthesis. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906614.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Phosphoproteins
  •  go-up   go-down


2. Goh PG, Moon HS, Sung JK, Jeong HY, Song KS: [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas]. Korean J Gastroenterol; 2010 Jan;55(1):73-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Peutz-Jeghers syndrome with intraductal papillary mucinous carcinoma of pancreas].
  • In particular, many studies have reported that patients with this syndrome have a high risk of gastrointestinal or extragastrointestinal malignancy including gastric, duodenal, jejunal, ileal, and colonic carcinoma as well as malignancies involving other organs such as the gallbladder, biliary tract, pancreas, tonsils, breast, and reproductive system.
  • In addition to that, there is no reported case of this syndrome with malignant tumor or intraductal papillary mucinous tumor of pancreas in Korea.
  • We experienced a case of PJS accompanying intraductal papillary mucinous carcinoma of the pancreas, therefore we report this case with literatures reviewed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Peutz-Jeghers Syndrome / diagnosis

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098071.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Sparr JA, Bandipalliam P, Redston MS, Syngal S: Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol; 2009 Feb;33(2):309-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a precancerous lesion with a well-described progression to carcinoma.
  • The patient's adenocarcinoma of the colon and IPMN of the pancreas showed identical immunohistochemical staining profiles with loss of expression of MSH2 and MSH6 proteins and high levels of microsatellite instability.
  • The immunohistochemical staining and microsatellite instability patterns of the adenocarcinoma of the colon and IPMN gives strong evidence to support the consideration of IPMN as part of the spectrum of lesions found in Lynch syndrome.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 1999 Nov;36(11):801-18 [10544223.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):444-9 [18398828.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2017-22 [11733352.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):537-42 [12808058.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):235-8 [14760534.001]
  • [Cites] Br J Cancer. 1985 Aug;52(2):271-3 [4027169.001]
  • [Cites] Cancer. 1991 Sep 1;68(5):1109-12 [1913482.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):677-85 [8431847.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1020-7 [8612988.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):470-3 [10022648.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):214-8 [10188721.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Arch Surg. 2006 Jan;141(1):51-6; discussion 56 [16415411.001]
  • [Cites] Hum Pathol. 2006 Nov;37(11):1498-502 [16996571.001]
  • [Cites] J Am Coll Surg. 2007 May;204(5):803-13; discussion 813-4 [17481488.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi [17996793.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • (PMID = 18987546.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA113433; United States / NCI NIH HHS / CA / K24 CA113433-04; United States / PHS HHS / / K24-113433
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ NIHMS77744; NLM/ PMC2631097
  •  go-up   go-down


Advertisement
4. Shamsadini S, Wadji MB, Shamsadini A: Surrounding ipsilateral eruptive seborrheic keratosis as a warning sign of intraductal breast carcinoma and Paget's disease (Leser Trelat sign). Dermatol Online J; 2006;12(6):27
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surrounding ipsilateral eruptive seborrheic keratosis as a warning sign of intraductal breast carcinoma and Paget's disease (Leser Trelat sign).
  • Paget disease of the breast, most often occurs in middle-aged women.
  • Leser-Trelat sign is a rare cutaneous manifestation of internal malignancy that is usually associated with visceral-type adenocarcinoma.
  • We report a patient with Paget disease of the nipple and intraductal carcinoma who presented with ipsilateral, eruptive grouped seborrheic keratoses of the areola and nipple of the breast.
  • [MeSH-major] Breast Diseases / etiology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Keratosis, Seborrheic / etiology. Paget's Disease, Mammary / diagnosis. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083907.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


5. Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, Nomura T: Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type. Pancreas; 2010 Jul;39(5):604-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary-mucinous neoplasms of the gastric and intestinal types may have less malignant potential than the pancreatobiliary type.
  • OBJECTIVES: Intraductal papillary-mucinous neoplasms (IPMNs) of the pancreas are classified into 4 types--gastric, intestinal, pancreatobiliary, and oncocytic--on the basis of their morphology and immunohistochemistry.
  • CONCLUSIONS: Intraductal papillary-mucinous neoplasm of the gastric and intestinal types may have less malignant potential than that of the pancreatobiliary type.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Bile Duct Neoplasms / pathology. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / pathology. Intestinal Neoplasms / pathology. Pancreatic Neoplasms / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124938.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer; 2005 Oct 31;93(9):1046-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of different histologic types of breast cancer.
  • Breast cancer is a heterogeneous disease, though little is known about some of its rarer forms, including certain histologic types.
  • Using Surveillance, Epidemiology, and End Results Program data on 135 157 invasive breast cancer cases diagnosed from 1992 to 2001, relationships between nine histologic types of breast cancer and various tumour characteristics were assessed.
  • The histologic types of breast cancer studied here differ greatly in their clinical presentations, and the differences in their hormone receptor profiles and grades point to their likely different aetiologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Jul;218(1):13-21 [8328824.001]
  • [Cites] JAMA. 2003 Mar 19;289(11):1421-4 [12636465.001]
  • [Cites] Arch Surg. 1979 Apr;114(4):485-8 [435063.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2254-9 [12805323.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2570-7 [10861435.001]
  • [Cites] JAMA. 2003 Jun 25;289(24):3254-63 [12824206.001]
  • [Cites] Natl Cancer Inst Monogr. 1981 Jun;(57):1-1082 [7278951.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):23-9 [15039595.001]
  • [Cites] Int J Epidemiol. 1992 Apr;21(2):222-8 [1428473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1128-35 [15247123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1175-81 [14652277.001]
  • [Cites] Breast. 2000 Oct;9(5):267-70; discussion 270 [14732176.001]
  • [Cites] JAMA. 2002 Feb 13;287(6):734-41 [11851540.001]
  • [Cites] Histopathology. 1982 Mar;6(2):149-61 [7076138.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):1-7 [8478135.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):549-59; discussion 559-61 [7574934.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):342-51 [14746851.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2149-53 [14557212.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600 [12101105.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):225-33 [12814201.001]
  • [Cites] Breast Cancer Res. 2004;6(3):R149-56 [15084238.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1673-7 [8156495.001]
  • (PMID = 16175185.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA132383; United States / NCI NIH HHS / CA / U56 CA096286; United States / NCI NIH HHS / CA / U56 CA096288
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2361680
  •  go-up   go-down


7. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


8. Obenauer S, Sohns C, Werner C, Grabbe E: Impact of breast density on computer-aided detection in full-field digital mammography. J Digit Imaging; 2006 Sep;19(3):258-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of breast density on computer-aided detection in full-field digital mammography.
  • In conclusion, there seems to be a tendency for breast tissue density to affect the detection rate of breast cancer when using the CAD system.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Mammography. Radiographic Image Enhancement. Radiographic Image Interpretation, Computer-Assisted
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Calcinosis / pathology. Calcinosis / radiography. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Germany. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Apr;219(1):192-202 [11274556.001]
  • [Cites] Rofo. 2000 Dec;172(12):957-64 [11199437.001]
  • [Cites] Eur Radiol. 2001;11(12):2454-9 [11734939.001]
  • [Cites] Eur Radiol. 2002 Jul;12(7):1697-702 [12111060.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):3015-7 [12439584.001]
  • [Cites] Clin Radiol. 2003 Feb;58(2):133-6 [12623042.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):687-93 [12933460.001]
  • [Cites] AJR Am J Roentgenol. 2003 Oct;181(4):1083-8 [14500236.001]
  • [Cites] CA Cancer J Clin. 1983 Jan-Feb;33(1):26-39 [6401574.001]
  • [Cites] Invest Radiol. 1990 Oct;25(10):1102-10 [2079409.001]
  • [Cites] Radiology. 1994 Apr;191(1):241-4 [8134580.001]
  • [Cites] Radiology. 1994 May;191(2):315-7 [8153298.001]
  • [Cites] Sci Am. 1996 Sep;275(3):56-9 [8701294.001]
  • [Cites] Acad Radiol. 1995 Aug;2(8):655-62 [9419620.001]
  • [Cites] Eur J Radiol. 1999 Jul;31(1):25-34 [10477095.001]
  • [Cites] Radiology. 1999 Sep;212(3):817-27 [10478252.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):439-44 [15671360.001]
  • [Cites] J Digit Imaging. 2005 Sep;18(3):227-33 [15827823.001]
  • [Cites] Eur J Radiol. 1999 Aug;31(2):97-109 [10565509.001]
  • [Cites] Radiology. 2000 May;215(2):554-62 [10796939.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7 [10880551.001]
  • [Cites] Rofo. 2001 Mar;173(3):218-23 [11293863.001]
  • (PMID = 16741664.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3045151
  •  go-up   go-down


9. Riall TS, Stager VM, Nealon WH, Townsend CM Jr, Kuo YF, Goodwin JS, Freeman JL: Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas. J Am Coll Surg; 2007 May;204(5):803-13; discussion 813-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of additional primary cancers in patients with invasive intraductal papillary mucinous neoplasms and sporadic pancreatic adenocarcinomas.
  • BACKGROUND: Recent small studies have reported an incidence of 23% to 39% for additional primary cancers in patients with intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
  • We determined the incidence of additional primary cancers that developed either before or after the diagnosis of invasive IPMN and compared it to the incidence of additional primary cancers in patients with sporadic pancreatic adenocarcinoma.
  • Ten point three percent had one or more extra-pancreatic primary cancers in addition to their pancreatic primary (10.3% in patients with sporadic adenocarcinoma and 10.1% in patients with invasive IPMNs, p = NS).
  • The most common sites of additional primary cancers were colorectal (20.1%), breast (19.9%), prostate (16.6%), urinary system (11.1%), and lung (9.8%).
  • Although not as high as previously reported in smaller studies, the incidence is significant and comparable to the incidence seen in patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Carcinoma, Papillary / epidemiology. Neoplasms, Multiple Primary / epidemiology. Pancreatic Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17481488.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Kimura W: Pancreatic lithiasis and intraductal papillary-mucinous neoplasm with special reference to the pathogenesis of lithiasis. J Hepatobiliary Pancreat Sci; 2010 Nov;17(6):776-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic lithiasis and intraductal papillary-mucinous neoplasm with special reference to the pathogenesis of lithiasis.
  • Mucin production in epithelia in intraductal papillary-mucinous neoplasm (IPMN) may not be strongly associated with the pathogenesis of pancreatic lithiasis.
  • An increase in intraductal pressure of the pancreatic duct may be somewhat related to the mechanism of stone formation.
  • [MeSH-minor] Adenocarcinoma, Mucinous. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pancreatitis, Chronic / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779665.001).
  • [ISSN] 1868-6982
  • [Journal-full-title] Journal of hepato-biliary-pancreatic sciences
  • [ISO-abbreviation] J Hepatobiliary Pancreat Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


11. Sakai T, Tsuchiya S, Hama Y, Matsuyama I, Fujimori M: Can cytological findings predict intraductal spread of breast cancer? Histopathological case-control study. Pathol Int; 2005 Dec;55(12):775-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can cytological findings predict intraductal spread of breast cancer? Histopathological case-control study.
  • An important predictive factor for local recurrence after breast-conserving therapy is the state of the surgical margin.
  • Samples from 69 cases of extensive ductal spread (EDS) in which it was thought that cancer cells had remained in the residual breast when the lumpectomy was performed with 2 cm margins, were retrieved and compared with 62 cases having almost the same clinical and pathological tumor size.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287492.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


12. Baumgaertner I, Corcos O, Couvelard A, Sauvanet A, Rebours V, Vullierme MP, Hentic O, Hammel P, Lévy P, Ruszniewski P: Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study. Am J Gastroenterol; 2008 Nov;103(11):2878-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study.
  • BACKGROUND: Some studies have suggested that intraductal papillary mucinous neoplasms (IPMN) of the pancreas could be associated with extrapancreatic cancers (EPC)--especially from gastric and colorectal origin.
  • The most frequent cancers in patients with IPMN and controls were: breast (30% in each group), prostate (10% and 13%, respectively, not significant [NS]), and colon/rectum (10 and 6%, respectively, NS).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853975.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Nicolas MM, Nayar R, Yeldandi A, De Frias DV: Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report. Acta Cytol; 2006 Nov-Dec;50(6):672-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of a postradiation breast epithelioid angiosarcoma mimicking adenocarcinoma. A case report.
  • We report a case of metastatic postradiation EAS to the lungs that was mistaken for adenocarcinoma.
  • An interpretation of adenocarcinoma was rendered during assessment for specimen adequacy.
  • The original breast tumor was typical of cribriform DCIS.
  • Review of the recurrent breast tumor (initially reported as DCIS) and a prior wedge resection of the lung nodules (reported as EAS) showed an epithelial-appearing tumor exhibiting an endothelial immunophenotype CONCLUSION: The cytologic features of EAS may resemble those of other neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Hemangiosarcoma / secondary. Lung Neoplasms / secondary. Neoplasms, Radiation-Induced / pathology. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152281.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Barbosa LA, Teixeira CR: Erythema multiforme associated with prophylactic use of phenytoin during cranial radiation therapy. Am J Health Syst Pharm; 2008 Jun 1;65(11):1048-50
Hazardous Substances Data Bank. PHENYTOIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: A 60-year-old woman with intraductal adenocarcinoma of the breast and cerebral metastasis who had an implanted central venous catheter arrived at the hospital for the treatment of cerebral metastasis.
  • CONCLUSION: A patient with intraductal adenocarcinoma of the breast and cerebral metastasis developed erythema multiforme after receiving concurrent phenytoin and radiation therapy.
  • [MeSH-major] Anticonvulsants / adverse effects. Brain Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Erythema Multiforme / etiology. Phenytoin / adverse effects
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Female. Humans. Middle Aged. Seizures / etiology. Seizures / prevention & control. Stevens-Johnson Syndrome / diagnosis. Stevens-Johnson Syndrome / etiology

  • Genetic Alliance. consumer health - Erythema Multiforme.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499877.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 6158TKW0C5 / Phenytoin
  •  go-up   go-down


15. Layfield LJ, Lewis C: In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol; 2007 Aug;29(4):239-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
  • STUDY DESIGN: Using immunohistochemistry, this study compares the Her-2/neu status in the in situ and invasive components of 200 cases of ductal carcinoma of the breast.
  • CONCLUSION: Significant heterogeneity exists between Her-2/neu expression in the in situ component and invasive components of adenocarcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879632.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


16. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


17. Lehman CD, DeMartini W, Anderson BO, Edge SB: Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw; 2009 Feb;7(2):193-201
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for breast MRI in the patient with newly diagnosed breast cancer.
  • Use of breast MRI in the preoperative evaluation of patients recently diagnosed with breast cancer has increased significantly over the past 10 years because of its well-documented high sensitivity for detecting otherwise occult breast cancer in the affected and contralateral breasts.
  • Equally important are growing concerns that the quality of breast MRI may vary significantly across practice sites, and therefore the published value of MRI may not be achieved for many patients.
  • This article describes the peer-reviewed, published clinical research trials evaluating breast MRI in patients with newly diagnosed breast cancer on which the National Comprehensive Cancer Network (NCCN) practice guidelines are based.
  • The current NCCN guidelines recommend that breast MRI be considered for patients with a newly diagnosed breast cancer to evaluate the extent of ipsilateral disease and to screen the contralateral breast, particularly for women at increased risk for mammographically occult disease.
  • In addition, the guidelines indicate that breast MRI may be used for patients with axillary nodal adenocarcinoma to identify the primary malignancy.
  • The guidelines stress the importance of having proper equipment, imaging technique, and provider training necessary to achieve high-quality breast MRI, and emphasize that MRI practice sites should have the ability to perform MRI-guided biopsy or needle localization.
  • In addition to describing the data regarding use of breast MRI in women with newly diagnosed cancer, this article provides recommendations for the performance of high-quality breast MRI and suggestions for future research.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adenocarcinoma / diagnosis. Axilla. Biopsy, Needle. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Female. Humans. Lymphatic Metastasis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Unknown Primary / pathology. Practice Guidelines as Topic. Sensitivity and Specificity. Surgery, Computer-Assisted

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200417.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


18. Ahrens P, Kreipe HH: [BRCA1- and BRCA2- associated breast carcinomas]. Pathologe; 2009 Dec;30 Suppl 2:207-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BRCA1- and BRCA2- associated breast carcinomas].
  • Breast cancers with a genetic BRCA1-/BRCA2 background differ from each other and sporadic cases.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Apoptosis Regulatory Proteins. Breast / pathology. Carcinoma, Ductal / genetics. Carcinoma, Ductal / pathology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / pathology. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Cell Division / genetics. Disease Progression. Female. Humans. Ki-67 Antigen / genetics. Neoplasm Staging. Prognosis. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795125.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 0 / Ki-67 Antigen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


19. Nash JW, Bhardwaj A, Wen P, Frankel WL: Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):59-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study.
  • Maspin, a member of the serpin family of serine protease inhibitors, has been shown to limit invasion and metastases in breast and prostate carcinomas.
  • Maspin expression has been documented using immunohistochemical studies in pancreatic adenocarcinoma and high-grade intraductal dysplasia.
  • Immunohistochemistry was performed on tissue microarrays made from 72 cases of pancreatic ductal adenocarcinoma and 24 cases of chronic pancreatitis.
  • Maspin may be helpful in differentiating ductal adenocarcinoma from chronic pancreatitis, once squamous metaplasia is ruled out.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536309.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


20. Istvanic S, Fischer AH, Banner BF, Eaton DM, Larkin AC, Khan A: Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes. Diagn Cytopathol; 2007 May;35(5):263-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell blocks of breast FNAs frequently allow diagnosis of invasion or histological classification of proliferative changes.
  • Two major limitations of breast fine needle aspiration (FNA) compared with core needle biopsies (CNB) are the inability to determine whether a cancer is invasive and to classify proliferative lesions.
  • We studied 40 consecutive "rapid cell blocks" from breast FNAs with surgical pathology follow-up to test whether cell blocks can overcome these limitations.
  • Cell blocks from 12 of 14 benign breast FNAs showed sufficient cells to assign a histologic diagnosis of no hyperplasia (1 case, confirmed on follow-up) and usual hyperplasia (11 cases; confirmed in eight of 11 on follow-up).
  • Specific histologic diagnoses included intraductal papilloma (2 cases), and in situ lobular neoplasia (2 cases).
  • Cell blocks complement smears and monolayers and appear to overcome major limitations of breast FNA.
  • [MeSH-major] Biopsy, Fine-Needle. Breast / pathology. Breast Neoplasms / pathology. Neoplasms, Ductal, Lobular, and Medullary / pathology. Paraffin Embedding / methods
  • [MeSH-minor] Adenocarcinoma / classification. Adenocarcinoma / pathology. Carcinoma in Situ / classification. Carcinoma in Situ / pathology. Carcinoma, Lobular / classification. Carcinoma, Lobular / pathology. Cell Proliferation. Female. Humans. Hyperplasia. Neoplasm Invasiveness. Papilloma, Intraductal / classification. Papilloma, Intraductal / pathology. Phyllodes Tumor / classification. Phyllodes Tumor / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17427225.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Zheng S, Zhang BL, Zhang RZ, Yang JL, Zou SM, Xue LY, Luo W, Yuan YL, Lü N: [Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):734-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].
  • OBJECTIVE: to investigate the pathologic basis of the difference between clinical response and pathologic response of breast carcinoma after neoadjuvant chemotherapy.
  • METHODS: two hundred and nine cases of breast cancer with neoadjuvant therapy were analyzed and clinical data were collected from June, 2005 to December, 2007.
  • Clinical examination, X-ray of breast and/or B ultrasonography of primary breast focus were taken before and after neoadjuvant chemotherapy.
  • Clinical responses of breast primary focus were evaluated according to RECIST (response evaluation criteria in solid tumors) version 1.1.Pathologic responses of breast primary focus were evaluated according to Miller and Payne (MP) grading system.
  • (1) Clinical responses basing on clinical examination showed complete response, partial response, stable disease and progressive response, in 33, 124, 41 and 11 cases respectively. (2) Eighty-seven cases had X-ray of breast taken before and after neoadjuvant chemotherapy.
  • Clinical response basing on X-ray, showed complete response, partial response and stable disease in 8, 42 and 37 cases respectively. (3) Pathologic responses of breast primary focus were as MP1 (14 cases), MP2 (35 cases), MP3 (106 cases), MP4 (36 cases) and MP5 (18 cases). (4) The clinical response basing on clinical examination were related to the pathologic response (χ(2) = 33.668, P = 0.001); and the clinical response basing on X-ray of breast were also related to the pathologic response (χ(2) = 22.404, P = 0.004). (5) The pathologic basis of the difference between the pathologic response and the clinical response basing on X-ray of breast were: embolism of carcinoma, mucinous carcinoma, intraductal carcinoma with ossifying-type calcification, nodular fibrosis and others.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiography. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Neoadjuvant Therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Disease Progression. Female. Humans. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215162.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


22. Uchida K, Yamashita A, Kawase K, Kamiya K: Screening ultrasonography revealed 15% of mammographically occult breast cancers. Breast Cancer; 2008;15(2):165-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening ultrasonography revealed 15% of mammographically occult breast cancers.
  • BACKGROUND: Mammography and physical examination (PE) are the recommended modalities for breast-cancer screening for women 40 years and older in Japan.
  • Mammography, however, cannot detect lesions in dense breast tissue, which is common in Japanese women.
  • Breast screening by ultrasound (US) is popular in Japan.
  • We studied which modality or combinations of modalities optimize breast cancer detection for Japanese women.
  • METHODS: From April 1993 through March 2005 we found 97 breast cancers in 9,082 women by screening examinations with mammography, US, and PE.
  • We compared the detection rates of these three modalities for breast cancer.
  • RESULTS: The detection rates of mammography, US, and PE for breast cancer were 83.5 (81 of 97 cancers), 75.3 (73 of 97 cancers), and 60.8% (59 of 97 cancers), respectively.
  • Ultrasonography detected 15% of the mammographically occult breast cancers.
  • CONCLUSION: Screening with the combination of mammography and US significantly increases the detection rate of breast cancer.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Breast Neoplasms / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18224382.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Abraham J, Flanagan M, Hazard H, Jubelirer S, Tirona MT, Vona-Davis L: Triple-negative breast cancer in West Virginia. W V Med J; 2009 Oct;105 Spec No:54-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple-negative breast cancer in West Virginia.
  • In 2007, the American Cancer Society ranked West Virginia 43rd in breast cancer incidence rates for individual states.
  • Despite our improvements in medical care, the advanced pathological characteristics of breast cancer at diagnosis receive little attention.
  • Consequently, we compared the changing pattern of early breast cancer in several cohort studies conducted at regional medical centers in West Virginia.
  • The data used in this analysis was derived from 320 women presenting at West Virginia University Hospital (WVUH) in Morgantown between 1999 and 2004, with a diagnosis of invasive breast cancer.
  • Only histologically documented adenocarcinomas of the breast were included.
  • For comparative purposes, details from the two regional centers were compared with tumor characteristics from a large longitudinal cohort of 2,484 breast cancers from the Women's Health Initiative (WHI) study.
  • Women diagnosed with triple-negative breast cancer at WVUH and CAMC had similar age distributions.
  • Combined breast cancer data from our medical centers show an increase in more advanced tumors and positive regional lymph node involvement at the time of diagnosis compared to national reports.
  • Other factors such as obesity, diabetes, poverty and access to mammography screening could be influencing the poorer outcomes for women with breast cancer in West Virginia.
  • [MeSH-major] Adenocarcinoma / epidemiology. Breast Neoplasms / epidemiology. Receptors, Estrogen. Receptors, Progesterone
  • [MeSH-minor] Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Female. Humans. Incidence. Longitudinal Studies. Male. Mass Screening. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. West Virginia / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999267.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


24. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T: Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer; 2010 Apr;17(2):118-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
  • BACKGROUND: Triple negative (TN) breast cancer is defined as a subtype that is negative for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2).
  • To clarify the characteristics of TN breast cancer, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed.
  • CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.
  • [MeSH-major] Breast Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult


25. Othman EQ, Kaur G, Mutee AF, Muhammad TS, Tan ML: Immunohistochemical expression of MAP1LC3A and MAP1LC3B protein in breast carcinoma tissues. J Clin Lab Anal; 2009;23(4):249-58
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of MAP1LC3A and MAP1LC3B protein in breast carcinoma tissues.
  • The aims of this study were to determine the MAP1LC3A and MAP1LC3B protein expression in both normal and cancer breast tissues and to determine the relationship between the expression of these proteins and type of tissues.
  • Immunohistochemistry assessments were carried out on tissue microarrays consisting of breast tissues.
  • MAP1LC3A expression was detected in 52/56 of normal breast tissue cores and 65/67 of breast cancer tissue cores.
  • MAP1LC3B expression was detected in 55/56 of normal breast tissue cores and 67/67 of breast cancer tissue cores.
  • MAP1LC3A and MAP1LC3B protein are expressed in the majority of normal and cancer breast tissues.
  • A large number of MAP1LC3A and MAP1LC3B positive breast cancer tissues cores have high proportion of stained cells (81-100%) as compared with normal breast tissues.
  • However, a significantly higher number of breast cancer tissues were found to express the MAP1LC3A protein with strong immunoreactivity as compared with the normal tissues, suggesting that MAP1LC3A may play a role in breast cancer development.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Immunoenzyme Techniques / methods. Microtubule-Associated Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Cell Count. Female. Fluorescent Antibody Technique, Direct. Humans. Middle Aged. Neoplasm Staging. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623642.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MAP1LC3A protein, human; 0 / MAP1LC3B protein, human; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


26. Otsuki Y, Yamada M, Shimizu S, Suwa K, Yoshida M, Tanioka F, Ogawa H, Nasuno H, Serizawa A, Kobayashi H: Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int; 2007 Jul;57(7):421-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases.
  • The purpose of the present paper was to evaluate the clinicopathological and biological features of 20 Japanese patients with solid-papillary carcinoma of the breast (SPC) or SPC associated with invasive breast cancer.
  • The incidence of SPC among all the breast cancers treated at two institutions was 1.1% and 1.7%, respectively.
  • When all the cases were classified and analyzed according to both the 2002 tumor node metastasis (TNM) classification system and the Nottingham histological grade, SPC patients, even those with invasive cancers, seemed to have longer disease-free survival compared to patients with the other invasive breast cancers of matching grade and stage.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / chemistry. Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / chemistry. Carcinoma, Neuroendocrine / classification. Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / surgery. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587241.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS: Expression of androgen receptors in primary breast cancer. Ann Oncol; 2010 Mar;21(3):488-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of androgen receptors in primary breast cancer.
  • BACKGROUND: To investigate the clinicopathological significance of androgen receptor (AR) expression in primary breast cancers.
  • AR expression was significant in patients with no elevated preoperative serum cancer antigen 15-3 levels, smaller tumor size, lower histologic grade and hormone receptor-positive and non-triple-negative breast cancer.
  • CONCLUSIONS: AR is expressed in a significant number of breast cancers and is associated with lower tumor burden and favorable differentiation.
  • There are many issues to be further investigated such as whether AR is an independent prognostic factor, whether it is a therapeutic target for the triple-negative breast cancers and whether it is associated with HER-2 signaling in ER-negative tumors.


28. Linda A, Zuiani C, Girometti R, Londero V, Machin P, Brondani G, Bazzocchi M: Unusual malignant tumors of the breast: MRI features and pathologic correlation. Eur J Radiol; 2010 Aug;75(2):178-84
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual malignant tumors of the breast: MRI features and pathologic correlation.
  • Unusual malignant breast tumors are well-differentiated subtypes of invasive ductal carcinoma, including mucinous, tubular, medullary and papillary carcinomas, and account for about 10% of malignant breast tumors.
  • They are increasingly being encountered during magnetic resonance imaging (MRI) examinations of the breast.
  • Therefore, breast radiologists should be aware of their appearance on MRI.
  • This review provides an overview of MRI characteristics of a range of unusual tumors (mucinous carcinoma, medullary carcinoma, tubular carcinoma, intraductal papillary carcinoma, intracystic papillary carcinoma and invasive papillary carcinoma), highlighting specific clues for diagnosis and correlating MRI and pathologic features.
  • Many unusual breast tumors exhibit MRI features similar to those of benign or low suspicious lesions (oval shape, well-defined margins, high signal intensity on T2-weighted images, continuous increase kinetics, i.e. type I dynamic curve), leading to a possible misdiagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast / pathology. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / pathology. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19446418.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


29. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ: Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol; 2009 Apr;33(4):534-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma.
  • Matrix-producing carcinoma (MPC) of the breast is a subtype of metaplastic carcinoma defined as an invasive breast carcinoma with a direct transition of carcinoma to cartilaginous or osseous matrix without an intervening spindle cell component.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Extracellular Matrix / pathology
  • [MeSH-minor] Adult. Aged. Calcinosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Chondrogenesis. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Metaplasia. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2010 Jan;34(1):125; author reply 125-6 [19956060.001]
  • (PMID = 19047898.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Motoyoshi A, Noguchi M, Earashi M, Zen Y, Fujii H: Histopathological and immunohistochemical evaluations of breast cancer treated with radiofrequency ablation. J Surg Oncol; 2010 Oct 1;102(5):385-91
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological and immunohistochemical evaluations of breast cancer treated with radiofrequency ablation.
  • BACKGROUND: Although RF ablation is a promising non-surgical ablation technique for the treatment of breast cancer, assessment of the efficacy requires not only imaging of tumor necrosis but also histological confirmation.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Catheter Ablation / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Cell Survival. DNA, Single-Stranded / metabolism. Dihydrolipoamide Dehydrogenase. Female. Humans. Middle Aged. Sentinel Lymph Node Biopsy. Staining and Labeling / methods. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:385-391. © 2009 Wiley-Liss, Inc.
  • (PMID = 19877159.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Single-Stranded; EC 1.8.1.4 / Dihydrolipoamide Dehydrogenase
  •  go-up   go-down


31. Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L: Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat; 2010 Dec;124(3):677-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
  • However, its role in the tumor progression of breast cancer has not been explored.
  • HAb18G expression was examined by immunohistochemistry in pathological sections of 1,637 breast tissue samples and by in situ hybridization in 41 cases of invasive breast carcinomas (BC).
  • While not detected in any cases of tumor-like conditions or benign tumors of breast, and only rarely in normal tissue (4.4%), HAb18G expression was gradually up-regulated from atypical ductal hyperplasia (27.3%), to ductal carcinoma-in situ (59.8%), and to BC (61.4%) (P < 0.01).
  • Significant differences of expression were also identified among the subgroups of BC examined: in decreasing order from invasive micropapillary carcinoma, ductal carcinoma, lobular carcinoma, papillary carcinoma, medullary carcinoma, to mucinous adenocarcinoma (P = 0.001), corresponding to their known clinical aggressiveness.
  • Further evaluation of this new marker in breast cancer is indicated.
  • [MeSH-major] Antigens, CD147 / analysis. Biomarkers, Tumor / analysis. Breast Neoplasms / immunology. Carcinoma / immunology. Carcinoma, Intraductal, Noninfiltrating / immunology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213083.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136894-56-9 / Antigens, CD147; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


32. Piñero A, Galindo PJ, Illana J, Nicolás F, Reus M, Hernández MD, Durán I, Canteras M, Parrilla P: Diagnostic efficiency of sestamibi gammagraphy and Doppler sonography in the preoperative assessment of breast lesions. Clin Transl Oncol; 2006 Feb;8(2):103-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic efficiency of sestamibi gammagraphy and Doppler sonography in the preoperative assessment of breast lesions.
  • INTRODUCTION: It would be desirable to have preoperative methods that allow an adequate selection of patients with breast lesions to rule out breast cancer.
  • The aim of the present study is to evaluate the efficiency of preoperative Sestamibi gammagraphy and Doppler sonography regarding the differential diagnosis of malignancy in breast lesions.
  • MATERIAL AND METHODS: A prospective observational study was conducted on 88 consecutive patients with breast lesions.
  • CONCLUSIONS: Sestamibi gammagraphy and Doppler sonography are two efficient exploratory techniques in the preoperative assessment of malignancy in breast lesions, especially for palpable lesions, and this efficiency is greater when they are combined.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Ultrasonography, Doppler
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adenocarcinoma / ultrasonography. Biopsy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radionuclide imaging. Breast Neoplasms, Male / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Carcinoma, Lobular / radiography. Carcinoma, Lobular / radionuclide imaging. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / ultrasonography. Female. Humans. Male. Mammography. Palpation. Predictive Value of Tests. Preoperative Care. Prospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16632424.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


33. Matsuura K, Yamaguchi Y, Osaki A, Ohara M, Okita R, Emi A, Murakami S, Arihiro K: FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncol Rep; 2009 Nov;22(5):1181-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients.
  • In the present study, we attempted to clarify the immunological status of SNs with or without micrometastasis in breast cancer patients.
  • Of the 71 metastasis-negative SNs, 11 showed positive bands on RT-PCR specific for mamma-globin [pN0(mol+)].
  • In patients with breast cancer, micrometastasis can stimulate Th1 response in SNs.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Papillary / genetics. Forkhead Transcription Factors / genetics. Gene Expression Regulation, Neoplastic / physiology. Lymph Nodes / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787238.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / RNA, Messenger; 0 / T-Box Domain Proteins; 0 / T-box transcription factor TBX21
  •  go-up   go-down


34. Fukuoka H, Moriuchi M, Yano H, Nagayasu T, Moriuchi H: No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer. J Med Virol; 2008 Aug;80(8):1447-51
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No association of mouse mammary tumor virus-related retrovirus with Japanese cases of breast cancer.
  • Mouse mammary tumor virus (MMTV) is the causative agent of breast tumors in mice.
  • Recently, DNA sequences homologous or closely related to MMTV env gene have been specifically detected in breast cancer tissue from significant numbers of American, Australian, and Tunisian women, suggesting a viral etiology for at least a part of human breast cancer.
  • However, the viral sequences have not been detected from any of breast cancer samples in several subsequent studies.
  • Thus, whether MMTV-related retrovirus is a causative agent of human breast cancer remains controversial.
  • To demonstrate if MMTV-related retrovirus is involved in Japanese cases of breast cancer, breast tissue specimens from 46 breast cancer patients and 3 patients with benign mammary tumors were investigated.
  • Thus, MMTV itself or MMTV-related retrovirus is not associated with breast carcinogenesis in Japanese women, and it is unclear whether this conclusion is merely a reflection of regional differences in its epidemics.
  • [MeSH-major] Breast Neoplasms. Gene Products, env / genetics. Genes, env. Mammary Tumor Virus, Mouse / isolation & purification
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / virology. Adult. Aged. Aged, 80 and over. Animals. Blotting, Southern. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / virology. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / virology. Cell Line, Tumor. Female. Fibroadenoma / epidemiology. Fibroadenoma / genetics. Fibroadenoma / virology. Humans. Japan / epidemiology. Mice. Middle Aged. Nucleic Acid Hybridization. Phyllodes Tumor / epidemiology. Phyllodes Tumor / genetics. Phyllodes Tumor / virology. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551605.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env
  •  go-up   go-down


35. Bratthauer GL, Saenger JS, Strauss BL: Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology; 2005 Dec;47(6):611-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
  • AIMS: The nuclear detection of p63 in myoepithelial cells of the breast has been useful in identifying possibly invasive carcinomas.
  • The aim was to determine whether this reaction is specific for p63 and indicative of all breast secretory cells.
  • METHODS: Thirty breast specimens were tested immunohistochemically for p63 protein.
  • The detection of p63 protein continues to have considerable value for the identification of myoepithelial cells and thus the determination of invasion, but will also have value in the determination of secretory carcinomas of the breast and in understanding their development.
  • [MeSH-major] Antibodies / metabolism. Breast / cytology. Breast / metabolism. Cell Differentiation. Genes, Tumor Suppressor. Phosphoproteins. Trans-Activators
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma / chemistry. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cytoplasm / metabolism. DNA-Binding Proteins. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Neoplasm Invasiveness. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324199.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


36. Cendán JC, Coco D, Copeland EM 3rd: Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins. J Am Coll Surg; 2005 Aug;201(2):194-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins.
  • BACKGROUND: My colleagues and I have been using intraoperative frozen-section analysis (FSA) to evaluate lumpectomy margins in an attempt to reduce the number of additional operations that patients with ductal carcinoma in situ or stage I and II breast cancer would have to endure.
  • We review our experience in breast-conservation therapy (BCT) at the University of Florida (Gainesville) to determine the effectiveness of this approach.
  • [MeSH-major] Breast Neoplasms / pathology. Frozen Sections / methods. Intraoperative Care / methods. Mastectomy, Segmental
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Algorithms. Biopsy, Needle / methods. Biopsy, Needle / standards. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Chi-Square Distribution. Decision Trees. False Negative Reactions. Female. Florida. Hospitals, University. Humans. Lymph Node Excision. Middle Aged. Retrospective Studies. Risk Factors. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038815.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Minor GI, Yashar CM, Spanos WJ Jr, Jose BO, Silverman CL, Carrascosa LA, Farmer M, Paris KJ: The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy. Breast J; 2006 Jan-Feb;12(1):48-52
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of radiation pneumonitis to treated lung volume in breast conservation therapy.
  • Breast conservation therapy has become a common modality for therapy of early stage breast cancer.
  • It is proposed that the lung volume treated during tangential radiation of the intact breast may be calculated from a measurement of the central lung distance.
  • From January 1, 1985, through December 31, 1998, 353 patients were treated with breast conservation therapy at the University of Louisville.
  • Breast conservation therapy is a well-tolerated modality for treatment of early stage breast cancer.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Lung / radiation effects. Radiation Pneumonitis / epidemiology. Radiation Pneumonitis / etiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiotherapy. Female. Humans. Kentucky / epidemiology. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409586.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis; 2007 Jan;28(1):130-5
Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
  • Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases.
  • Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue.
  • Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer.
  • All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).
  • This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animals. Carcinogens / toxicity. Carcinoma, Intraductal, Noninfiltrating / chemically induced. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation / drug effects. Cells, Cultured. Cyclooxygenase 2 / metabolism. Disease Progression. Epithelium / drug effects. Estrogen Receptor alpha / metabolism. Estrogens / toxicity. Female. Hyperplasia / chemically induced. Hyperplasia / pathology. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Methylnitrosourea / toxicity. Precancerous Conditions. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891317.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA089019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Ki-67 Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 684-93-5 / Methylnitrosourea; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


39. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO: Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol; 2008 Apr;32(4):513-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family.
  • We have previously provided evidence showing an association between some precursor lesions with low nuclear grade breast carcinomas (LNGBCs).
  • The ER-alpha/ER-beta expression ratio increased during carcinogenesis, as did expression of cyclin D1 and Bcl-2. p53 immunopositivity was found 3% in LNGBC versus 43% in high nuclear grade breast carcinoma (HNGBC), whereas ataxia telangiectasia mutated expression was absent or reduced in 22% of LNGBC versus 53% of HNGBC cases.
  • These may represent a family of precursor, in situ and invasive neoplastic lesions belonging to the luminal "A" subclass of breast cancer.
  • Ataxia telangiectasia mutated may be one of the alternative regulatory mechanisms to TP53 mutation or dysfunction in low-grade and high-grade breast carcinoma.
  • [MeSH-major] Breast Neoplasms / chemistry. Breast Neoplasms / pathology. Mammary Glands, Human / chemistry. Mammary Glands, Human / pathology. Precancerous Conditions / chemistry. Precancerous Conditions / pathology
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Ataxia Telangiectasia Mutated Proteins. Carcinoma, Intraductal, Noninfiltrating / chemistry. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / chemistry. Carcinoma, Lobular / pathology. Cell Cycle Proteins / analysis. Cyclin D. Cyclins / analysis. DNA-Binding Proteins / analysis. Estrogen Receptor alpha / analysis. Estrogen Receptor beta / analysis. Evolution, Molecular. Female. Humans. Hyperplasia. Immunohistochemistry. Keratin-18 / analysis. Keratin-19 / analysis. Keratin-8 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin D; 0 / Cyclins; 0 / DNA-Binding Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / KRT18 protein, human; 0 / KRT8 protein, human; 0 / Keratin-18; 0 / Keratin-19; 0 / Keratin-8; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


40. Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP: Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol; 2009 Nov;33(11):1646-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ.
  • Low-grade precursor lesions, such flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (lg-DCIS), and lobular neoplasia (LN) often coexist with invasive tubular carcinomas (TCs) of the breast.
  • Our data indicate, that in the majority of cases lg-DCIS and FEA are directly related to tubular breast cancer with a possible precursor role.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675453.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


41. Farshid G, Pieterse S, King JM, Robinson J: Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications. Breast J; 2005 Jan-Feb;11(1):15-22
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications.
  • Most earlier reports of mucocele-like lesions (MLL) of the breast have dealt with symptomatic cases in premenopausal women or lesions found incidentally in breast biopsies performed for other reasons.
  • The diagnosis of this lesion has special challenges in the setting of mammographic screening for breast cancer because the imaging characteristics of MLL may mimic those of ductal carcinoma in situ (DCIS), while mucinous carcinoma enters the differential diagnosis on cytologic grounds.
  • Correlating the cytomorphology of mucinous lesions of the breast with their mammographic appearance may permit more precise preoperative diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / radiography. Breast Neoplasms / epidemiology. Breast Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Calcinosis / epidemiology. Calcinosis / etiology. Calcinosis / pathology. Calcinosis / radiography. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Female. Humans. Mammography. Medical Records. Middle Aged. Precancerous Conditions / epidemiology. Precancerous Conditions / etiology. Precancerous Conditions / pathology. Precancerous Conditions / radiography. Predictive Value of Tests. Retrospective Studies. South Australia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647073.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Okafuji T, Yabuuchi H, Sakai S, Soeda H, Matsuo Y, Inoue T, Hatakenaka M, Takahashi N, Kuroki S, Tokunaga E, Honda H: MR imaging features of pure mucinous carcinoma of the breast. Eur J Radiol; 2006 Dec;60(3):405-13
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging features of pure mucinous carcinoma of the breast.
  • OBJECTIVE: To characterize MR imaging features of pure mucinous carcinoma of the breast.
  • MATERIALS AND METHODS: MR images obtained from 16 women (age range, 29-81; mean age, 57 years) with pure mucinous carcinoma of the breast determined at surgery were reviewed.
  • Non-mass-like enhancement was compared with the presence of extensive intraductal component (EIC) on histopathological findings.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16963218.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


43. Hatzung G, Grunwald S, Zygmunt M, Geaid AA, Behrndt PO, Isermann R, Kohlmann T, Ohlinger R: Sonoelastography in the diagnosis of malignant and benign breast lesions: initial clinical experiences. Ultraschall Med; 2010 Dec;31(6):596-603
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonoelastography in the diagnosis of malignant and benign breast lesions: initial clinical experiences.
  • PURPOSE: This prospective study aimed to compare sonoelastography, B-mode ultrasonography, and mammography in terms of their ability to distinguish benign from malignant breast lesions.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Elasticity Imaging Techniques / methods. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / ultrasonography. Adult. Aged. Biopsy / methods. Breast / pathology. Carcinoma, Ductal / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / ultrasonography. Female. Fibroadenoma / pathology. Fibroadenoma / ultrasonography. Humans. Middle Aged. Papilloma / pathology. Papilloma / ultrasonography. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20614414.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH: The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol; 2007 Sep-Oct;8(5):390-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors.
  • OBJECTIVE: We wanted to evaluate the role of diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) for detecting breast tumors, as compared with the T1- and T2-weighted images.
  • MATERIALS AND METHODS: Forty-one female patients underwent breast MRI, and this included the T1-, T2-, DWI and dynamic contrast-enhanced images.
  • Fifty-six breast lesions were detected on DWI and the histological diagnoses were as follows: 43 invasive ductal carcinomas, one mucinous carcinoma, one mixed infiltrative and mucinous carcinoma, seven ductal carcinomas in situ (DCIS), and four benign tumors.
  • First, we compared the detectability of breast lesions on DWI with that of the T1- and T2-weighted images.
  • We then compared the ADCs of the malignant and benign breast lesions to the ADCs of the normal fibroglandular tissue.
  • The detectabilities of breast lesions on the T1- and T2-weighted imaging were 61.5% (40/65) and 75.4% (49/65), respectively.
  • CONCLUSION: DWI has a high sensitivity for detecting breast tumors, and especially for detecting malignant breast tumors.
  • DWI was an effective imaging technique for detecting breast lesions, as compared to using the T1- and T2-weighted images.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diffusion Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Contrast Media / administration & dosage. Female. Gadolinium DTPA. Humans. Image Enhancement / methods. Imaging, Three-Dimensional / methods. Middle Aged. Observer Variation. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):975-83 [11105039.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Radiology. 2001 Jul;220(1):13-30 [11425968.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1403-9 [12034606.001]
  • [Cites] J Magn Reson Imaging. 2002 Jun;15(6):693-704 [12112520.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6 [12488758.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):169-84 [12595101.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):654-61 [15390142.001]
  • [Cites] Stroke. 1997 Mar;28(3):481-2 [9056599.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] Radiology. 1998 Sep;208(3):605-9 [9722835.001]
  • [Cites] J Magn Reson Imaging. 1999 Jan;9(1):53-60 [10030650.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] JAMA. 2004 Dec 8;292(22):2735-42 [15585733.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):1014-9 [11105044.001]
  • (PMID = 17923781.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ PMC2626812
  •  go-up   go-down


45. Veronesi U, Luini A, Botteri E, Zurrida S, Monti S, Galimberti V, Cassano E, Latronico A, Pizzamiglio M, Viale G, Vezzoli D, Rotmensz N, Musmeci S, Bassi F, Burgoa L, Maisonneuve P, Paganelli G, Veronesi P: Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases. Oncologist; 2010;15(12):1248-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonpalpable breast carcinomas: long-term evaluation of 1,258 cases.
  • INTRODUCTION: In recent decades, a steady improvement in imaging diagnostics has been observed together with a rising adherence to regular clinical breast examinations.
  • All patients underwent radioguided occult lesion localization (ROLL), axillary dissection when appropriate, whole breast radiotherapy, or partial breast intraoperative irradiation and received tailored adjuvant systemic treatment.
  • Imaging showed a breast nodule in half of the cases and a breast nodule accompanied by microcalcifications in 9%.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Calcinosis / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiography. Carcinoma in Situ / therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Intraductal, Noninfiltrating / therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Lobular / therapy. Female. Humans. Magnetic Resonance Imaging. Mammography. Middle Aged. Neoplasm Staging. Palpation. Prognosis. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med. 2002 Jun;46(2):145-51 [12114878.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1839-40 [12453850.001]
  • [Cites] Lancet. 2003 Apr 26;361(9367):1405-10 [12727392.001]
  • [Cites] N Engl J Med. 1976 Jul 29;295(5):259-60 [934190.001]
  • [Cites] J Surg Oncol. 1978;10(3):251-71 [651373.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1219-28 [20406961.001]
  • [Cites] Radiology. 1984 Mar;150(3):761-6 [6695077.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):522-5 [10215829.001]
  • [Cites] Lancet Oncol. 2006 Dec;7(12):983-90 [17138219.001]
  • [Cites] Eur J Cancer. 2009 May;45(8):1381-8 [19128957.001]
  • [Cites] J Med Screen. 2010;17(1):25-30 [20356942.001]
  • [Cites] Radiology. 1984 Feb;150(2):523-30 [6691113.001]
  • (PMID = 21147866.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227928
  •  go-up   go-down


46. Ellberg C, Jönsson G, Olsson H: Can a phenotype for recessive inheritance in breast cancer be defined? Fam Cancer; 2010 Dec;9(4):525-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can a phenotype for recessive inheritance in breast cancer be defined?
  • While a dominant inheritance of breast cancer (vertical inheritance) is well known, less is known about a possible recessive inheritance (horizontal inheritance).
  • In a clinical series of 1676 breast cancer patient's family history was scored as vertical (grandmother-aunt-mother-sister-daughter) or horizontal (sister-sister) and related to histopathological tumor type, presence of germline mutations, bilaterality, multifocality, screening, parity, hormone replacement therapy (HRT) use and age at diagnosis.
  • Factors associated with a horizontal family history were found, defining a possible phenotype for a recessive inheritance: tubular breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / mortality. Genes, Recessive. Genetic Predisposition to Disease. Mutation / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Adenocarcinoma / therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Aged, 80 and over. BRCA1 Protein / genetics. BRCA2 Protein / genetics. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / mortality. Carcinoma, Intraductal, Noninfiltrating / therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / mortality. Carcinoma, Lobular / therapy. Carcinoma, Medullary / genetics. Carcinoma, Medullary / mortality. Carcinoma, Medullary / therapy. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Genotype. Hormone Replacement Therapy. Humans. Lymphatic Metastasis. Middle Aged. Phenotype. Polymerase Chain Reaction. Pregnancy. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Tumor Suppressor Protein p53 / genetics. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20549370.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


47. Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol; 2008 Feb;12(1):33-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.
  • Basal-like tumors are a newly recognized estrogen receptor (ER) negative and HER2 negative breast cancer subtype that express basal epithelial genes and are associated with poor survival.
  • The current study examined the rates and patterns of alphaB-crystallin expression in whole tissue sections of human breast, including normal tissue, proliferative lesions, in situ and invasive carcinomas (ER positive, HER2 positive, basal-like, and metaplastic cancers).
  • In normal breast tissue, proliferative lesions and in situ carcinomas, alphaB-crystallin expression was restricted to the myoepithelial cell compartment of ductal and lobular units.
  • Conversely, no staining for alphaB-crystallin was observed in nonbasal-like (ie, ER positive or HER2 positive) breast carcinomas.
  • Taken together, our results indicate that alphaB-crystallin is a sensitive (81%) and specific (100%) marker for basal-like breast carcinomas.
  • Moreover, the high rates of expression of alphaB-crystallin in metaplastic breast carcinomas (86%) suggest that these tumors may represent a histologically distinctive subset of basal-like breast tumors with a similar underlying molecular etiology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. alpha-Crystallin B Chain / metabolism
  • [MeSH-minor] Breast Cyst / metabolism. Breast Cyst / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia. Neoplasm Invasiveness. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164413.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA89018; United States / NCI NIH HHS / CA / R01CA097198
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Crystallin B Chain
  •  go-up   go-down


48. Fernández-Aguilar S, Simon P, Buxant F, Simonart T, Noël JC: Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas. Virchows Arch; 2005 Oct;447(4):683-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas.
  • Ductal intra-epithelial lesions of the breast are associated with invasive neoplasms and comprise a large spectrum of histological patterns.
  • We have examined 23 cases of pure tubular carcinomas (TCs) of the breast and 53 cases of invasive ductal low-grade carcinomas to determine the relationship and distribution of intra-epithelial lesions, mainly of ductal in situ carcinoma type, but including also lobular intra-epithelial neoplasia (LIN) in both entities.
  • These results suggest that invasive pure TC and low-grade ductal carcinomas of the breast are different lesions, and support the fact that TC, of low histopathological grade, is a particular distinct tumoural entity.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091953.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H, Zhu M: N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer; 2010;10:123
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
  • Recently it was found that GalNAc-T14 mRNA is heterogeneously expressed in breast carcinomas compared to normal tissue, however the expression profile of GalNAc-T14 protein in breast carcinomas compared to normal tissue is still unknown.
  • In this study, we assessed the expression profile of GalNAc-T14 protein in malignant and non-malignant breast tissues by immunohistochemistry to evaluate whether GalNAc-T14 might be a potential biomarker for breast cancer.
  • METHODS: In formalin-fixed tissues, the expression level of GalNAc-T14 protein was evaluated by immunohistochemistry assay in breast tissues.
  • RESULTS: Our results showed that GalNAc-T14 was heterogeneously expressed in breast carcinomas compared to non-malignant tissue.
  • GalNAc-T14 expression was observed in 47/56 (83.9%) carcinoma samples, 7/48 (14.6%) non-malignant breast tissue samples.
  • For this enzyme a significant association with invasive ductal type, mucinous adenocarcinoma and ductal carcinoma in situ (DCIS) type was found.
  • CONCLUSION: Our results provide evidence that GalNAc-T14 may be a potential biomarker for breast cancer by immunohistochemistry.
  • GalNAc-T14 expression can provide new insights about breast cancer glycobiology.
  • [MeSH-major] Adenocarcinoma, Mucinous / enzymology. Biomarkers, Tumor / analysis. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Intraductal, Noninfiltrating / enzymology. Immunohistochemistry. N-Acetylgalactosaminyltransferases / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 1999 Oct 29;460(2):226-30 [10544240.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1070-7 [17767167.001]
  • [Cites] Gene. 2000 Apr 4;246(1-2):347-56 [10767557.001]
  • [Cites] Biochim Biophys Acta. 2000 Sep 7;1493(1-2):264-8 [10978536.001]
  • [Cites] J Gastroenterol. 2000;35(11):840-8 [11085493.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Glycobiology. 2001 Sep;11(9):731-40 [11555617.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] FEBS Lett. 2002 Jul 31;524(1-3):211-8 [12135769.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):751-5 [12232759.001]
  • [Cites] FEBS Lett. 2002 Nov 6;531(2):115-21 [12417297.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):738-44 [12507512.001]
  • [Cites] Pathobiology. 2004;71(1):12-8 [14555840.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):436-42 [14735190.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2090-9 [15041730.001]
  • [Cites] J Surg Oncol. 2004 Apr 1;86(1):28-33 [15048677.001]
  • [Cites] FEBS Lett. 2004 May 21;566(1-3):17-24 [15147861.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Biochim Biophys Acta. 1982 Dec 21;695(2):113-76 [6763877.001]
  • [Cites] Cancer Res. 1989 Jan 1;49(1):197-204 [2908846.001]
  • [Cites] Lab Invest. 1990 Dec;63(6):780-91 [1979361.001]
  • [Cites] Semin Cancer Biol. 1991 Apr;2(2):129-39 [1680492.001]
  • [Cites] Dis Markers. 1992 Mar-Apr;10(2):81-94 [1281060.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3632-7 [8101764.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2323-30 [8104679.001]
  • [Cites] Biochim Biophys Acta. 1994 May 27;1198(1):1-10 [8199192.001]
  • [Cites] Cancer Detect Prev. 1995;19(2):173-82 [7750105.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24156-65 [7592619.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17006-12 [8663203.001]
  • [Cites] J Mol Med (Berl). 1997 Aug;75(8):594-602 [9297627.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30472-81 [9804815.001]
  • [Cites] Glycobiology. 1999 Jan;9(1):43-52 [9884405.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25362-70 [10464263.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):950-6 [15609297.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7880-7 [16140958.001]
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):317-28 [16260590.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):267-76 [17361208.001]
  • [Cites] Acta Histochem. 2007;109(4):273-84 [17448526.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • (PMID = 20356418.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 2.4.1.41 / UDP-N-acetyl-D-galactosamine polypeptide N-acetylgalactosaminyltransferase 14, human
  • [Other-IDs] NLM/ PMC2873381
  •  go-up   go-down


50. Algara López M, Sanz Latiesas X, Foro Arnalot P, Lacruz Bassols M, Reig Castillejo A, Quera Jordana J, Membrive Conejo I, Lozano Galán J, Rodríguez de Dios N: Risk factors of local relapse in breast cancer: the importance of age. Clin Transl Oncol; 2007 Feb;9(2):110-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors of local relapse in breast cancer: the importance of age.
  • PURPOSE: The objective of the present analysis is to know what risk factors affect local relapse in breast cancer.
  • METHODS AND MATERIALS: A total of 1165 patients diagnosed with early breast cancer were included.
  • Other risk factors such as tumour size, intraductal carcinoma or margin status could be masked by an increase of radiation dose.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / radiotherapy. Breast Neoplasms / epidemiology. Breast Neoplasms / radiotherapy. Neoplasm Recurrence, Local / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329223.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Sveinsdottir SG, Alexiusdottir K, Saemundsdottir J, Sigurdsson A, Kostic J, Gudmundsson L, Kristjansson K, Masson G, Fackenthal JD, Adebamowo C, Ogundiran T, Olopade OI, Haiman CA, Lindblom A, Mayordomo JI, Kiemeney LA, Gulcher JR, Rafnar T, Thorsteinsdottir U, Johannsson OT, Kong A, Stefansson K: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet; 2008 Jun;40(6):703-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.
  • We carried out a genome-wide association study of breast cancer predisposition with replication and refinement studies involving 6,145 cases and 33,016 controls and identified two SNPs (rs4415084 and rs10941679) on 5p12 that confer risk, preferentially for estrogen receptor (ER)-positive tumors (OR = 1.27, P = 2.5 x 10(-12) for rs10941679).
  • A recently reported signal in FGFR2 was also found to associate specifically with ER-positive breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Chromosomes, Human, Pair 5 / genetics. Genetic Predisposition to Disease. Genetic Variation. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Apoptosis. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Carcinoma, Medullary / genetics. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Case-Control Studies. Cohort Studies. Female. Humans. International Agencies. Male. Middle Aged. Polymorphism, Single Nucleotide. Prognosis. Receptor, Fibroblast Growth Factor, Type 2 / genetics. Receptor, Fibroblast Growth Factor, Type 2 / metabolism. Ribosomal Proteins / genetics. Ribosomal Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438407.001).
  • [ISSN] 1546-1718
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA89085-01A
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Ribosomal Proteins; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  •  go-up   go-down


52. de Candia P, Akram M, Benezra R, Brogi E: Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma. Hum Pathol; 2006 Aug;37(8):1032-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
  • In addition, we evaluated Id4 mRNA in atypical ductal hyperplasia from 5 other women and in normal breast tissue from yet another 5 women with no history of breast malignancy or atypia.
  • Id4 mRNA was present in the normal ER-negative mammary epithelium in all cases; in contrast, the ER-positive cells present in the normal breast were Id4 negative.
  • Our data show that Id4 is constitutively expressed in the normal human mammary epithelium but is suppressed in ER-positive breast carcinomas and preneoplastic lesions.
  • These results support a possible role of Id4 as a tumor suppressor factor in the human breast and suggest that the expression of Id4 in the mammary ductal epithelium may be regulated by estrogen.
  • Further investigations are required to define the functions of Id4 in the human normal breast and in mammary neoplasia.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Helix-Loop-Helix Motifs. Inhibitor of Differentiation Proteins / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / cytology. Breast / metabolism. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Middle Aged. Neoplasm Staging. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867866.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Estrogen
  •  go-up   go-down


53. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H: Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol; 2008 Apr;38(4):250-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
  • OBJECTIVE: Using integrated 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT), the clinical significance of 18F-FDG uptake was evaluated in patients with primary breast cancer.
  • METHODS: Clinicopathological correlation with the level of maximum standardized uptake values (SUV) 60 min obtained from preoperative 18F-FDG PET/CT were examined in 152 patients with primary breast cancer.
  • Multivariate analyses showed tumor invasive size, nuclear grade and estrogen receptor negativity were significantly correlated with SUV in primary breast cancer (P < 0.0001,< 0.0001, and < 0.012, respectively), and nuclear grade was significantly correlated with SUV in tumors of invasive size 2 cm or less (P < 0.0001).
  • CONCLUSIONS: High uptake of 18F-FDG would be predictive of poor prognosis in patients with primary breast cancer, and aggressive features of cancer cells in patients with early breast cancer.
  • 18F-FDG PET/CT could be a useful tool to pre-therapeutically predict biological characteristics and baseline risk of breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Fluorodeoxyglucose F18 / metabolism. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Aged, 80 and over. Analysis of Variance. Biomarkers, Tumor / analysis. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Lobular / metabolism. Contrast Media. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Radiopharmaceuticals / metabolism. Receptor, ErbB-2 / analysis. Receptors, Estrogen. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407934.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


54. Stell VH, Flippo-Morton TS, Norton HJ, White RL Jr: Effect of intraoperative radiocolloid injection on sentinel lymph node biopsy in patients with breast cancer. Ann Surg Oncol; 2009 Aug;16(8):2300-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of intraoperative radiocolloid injection on sentinel lymph node biopsy in patients with breast cancer.
  • BACKGROUND: Preoperative injection of radiocolloid before a sentinel lymph node (SLN) biopsy is painful for patients with breast cancer.
  • Patients in the preoperative injection (PO) group were injected by radiologists in the breast imaging center.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Lymph Nodes / radionuclide imaging. Radiopharmaceuticals. Technetium Tc 99m Sulfur Colloid
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radionuclide imaging. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radionuclide imaging. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radionuclide imaging. Female. Humans. Intraoperative Period. Middle Aged. Neoplasm Invasiveness. Preoperative Care. Prognosis. Prospective Studies. Retrospective Studies. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484310.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


55. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjärvi T, Kallioniemi A: The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat; 2006 Feb;95(3):257-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
  • Here we explored the role of PPM1D aberrations in primary breast cancer.
  • On the other hand, these key cellular proteins are likely to be regulated through a complex fashion in breast cancer and apparently PPM1D represents only one of these mechanisms.
  • Taken together, our findings substantiate an important role for PPM1D in breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Amplification. Gene Expression Regulation, Enzymologic. Phosphoprotein Phosphatases / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Adult. Aged. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction


56. Liu M, Chen W, Li XR, Li JL, Wang JD, Zhang YJ, Zheng YQ, Wei LX: [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy]. Zhonghua Bing Li Xue Za Zhi; 2010 Nov;39(11):739-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on diagnostic accuracy of ultrasound-guided core needle breast biopsy].
  • OBJECTIVE: to evaluate the diagnostic accuracy of ultrasound-guided core needle biopsy of breast tumors.
  • METHODS: six hundred and sixty-seven cases of core needle biopsy of breast encountered during the period from January, 2004 to June, 2007 were retrieved from the archival file and retrospectively reviewed.
  • RESULTS: three hundred and eighty-two patients had core needle biopsy diagnosis followed by local excision, breast conservation surgery or mastectomy.
  • CONCLUSION: in order to improve the diagnostic accuracy of core needle biopsy of breast tumors, recognition of the limitation of the procedure, application of immunohistochemistry and awareness of potentially rare entities are important.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / ultrasonography. Antigens, CD56 / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Intraductal, Noninfiltrating / ultrasonography. False Negative Reactions. Female. Humans. Keratin-5 / metabolism. Mastectomy / methods. Membrane Proteins / metabolism. Retrospective Studies. Ultrasonography, Interventional / methods. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21215163.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / CKAP4 protein, human; 0 / Keratin-5; 0 / Membrane Proteins
  •  go-up   go-down


57. Uematsu T, Kasami M: MR imaging findings of benign and malignant circumscribed breast masses: part 1. Solid circumscribed masses. Jpn J Radiol; 2009 Dec;27(10):395-404
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging findings of benign and malignant circumscribed breast masses: part 1. Solid circumscribed masses.
  • The purpose of our study was to review the magnetic resonance (MR) imaging findings and pathological diagnoses of benign and malignant solid circumscribed breast masses.
  • This article reviews the MR imaging findings of solid circumscribed breast masses.
  • A strategy for the diagnosis of solid circumscribed breast masses with MR imaging is herein presented that incorporates the signal intensity characteristics on T(1)- and T(2)-weighted images with the kinetic curve assessment reflected by the temporal and spatial uptake of contrast medium.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Magnetic Resonance Imaging. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Medullary / diagnosis. Contrast Media. Female. Fibroadenoma / diagnosis. Humans. Image Interpretation, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20035410.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 15
  •  go-up   go-down


58. Wechselberger C, Strizzi L, Kenney N, Hirota M, Sun Y, Ebert A, Orozco O, Bianco C, Khan NI, Wallace-Jones B, Normanno N, Adkins H, Sanicola M, Salomon DS: Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene; 2005 Jun 9;24(25):4094-105
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma.
  • Human Cripto-1 (CR-1) is overexpressed in approximately 80% of human breast, colon and lung carcinomas.
  • Virgin female MMTV/CR-1 Tg mice exhibited enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules and condensation of the mammary stroma.
  • [MeSH-major] Adenocarcinoma / genetics. Epidermal Growth Factor / genetics. Mammary Glands, Animal / pathology. Mammary Neoplasms, Animal / genetics. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897912.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Complementary; 0 / GPI-Linked Proteins; 0 / Growth Substances; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


59. Ang EZ, Nguyen HT, Sim HL, Putti TC, Lim LH: Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells. Mol Cancer Res; 2009 Feb;7(2):266-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells.
  • Estrogen, a naturally occurring female steroid growth hormone, has been implicated as a major risk factor for the development of breast cancer.
  • Recent research into this disease has also correlated Annexin-1 (ANXA1), a glucocorticoid-inducible protein, with the development of breast tumorigenesis.
  • ANXA1 is lost in many cancers, including breast cancer, and this may result in a functional promotion of tumor growth.
  • Exposure of MCF-7 breast cancer cells to high physiologic levels (up to 100 nmol/L) of estrogen leads to an up-regulation of ANXA1 expression partially through the activation of cyclic AMP-responsive element binding protein and dependency on activation of the estrogen receptor.
  • We confirm that ANXA1 is lost in clinical breast cancer, indicating that the antiproliferative protective function of ANXA1 against high levels of estrogen may be lost.
  • [MeSH-major] Annexin A1 / physiology. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Cell Proliferation. Estrogens / pharmacology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Blotting, Western. Carcinogens / toxicity. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Medullary / metabolism. Carcinoma, Medullary / pathology. Cell Line, Tumor. Cyclic AMP Response Element-Binding Protein / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Estrogen Receptor alpha / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Luciferases / metabolism. Mice. Mice, Inbred BALB C. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Up-Regulation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208747.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Carcinogens; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / estrogen receptor alpha, human; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 1.13.12.- / Luciferases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


60. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H: FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4415-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
  • FOXA1 is expressed in breast cancer cells.
  • The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers.
  • RESULTS: FOXA1 expression (score >3) was seen in 300 of 404 breast cancers and it correlated with ER (P = 0.000001), PR (P = 0.00001), and luminal A subtype (P = 0.000001).
  • Univariate analysis showed nodal status (P = 0.0000012), tumor size (P = 0.00001), FOXA1 (P = 0.0004), and ER (P = 0.012) to be predictors of breast cancer-specific survival.
  • CONCLUSION: FOXA1 expression correlates with luminal subtype A breast cancer and it is significant predictor of cancer-specific survival in patients with ER-positive tumors.
  • Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in clinical treatment decisions.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Epithelium / metabolism. Hepatocyte Nuclear Factor 3-alpha / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / mortality. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / mortality. Carcinoma, Lobular / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Kaplan-Meier Estimate. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671124.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97403; United States / NCI NIH HHS / CA / R01 CA101227-01; United States / NCI NIH HHS / CA / R01 CA89153
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXA1 protein, human; 0 / Hepatocyte Nuclear Factor 3-alpha; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


61. Lim M, Bellon JR, Gelman R, Silver B, Recht A, Schnitt SJ, Harris JR: A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1149-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer.
  • PURPOSE: The effectiveness of radiation therapy (RT) in reducing local recurrence after breast-conserving surgery (BCS) in unselected patients with early stage invasive breast cancer has been demonstrated in multiple randomized trials.
  • In 1986, we initiated a prospective one-arm trial of BCS alone for highly selected breast-cancer patients.
  • Patients were required to have a unicentric, T1, pathologic node-negative invasive ductal, mucinous, or tubular carcinoma without an extensive intraductal component or lymphatic-vessel invasion.
  • Other sites of first failure included 1 ipsilateral axilla, 2 contralateral breast cancers, and 4 distant metastases.
  • Nine patients have died, 4 of metastatic breast cancer and 5 of unrelated causes.
  • [MeSH-major] Breast Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local / surgery. Poisson Distribution. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750330.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Zhang CX, Ho SC, Chen YM, Fu JH, Cheng SZ, Lin FY: Greater vegetable and fruit intake is associated with a lower risk of breast cancer among Chinese women. Int J Cancer; 2009 Jul 1;125(1):181-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Greater vegetable and fruit intake is associated with a lower risk of breast cancer among Chinese women.
  • The effect of vegetable and fruit consumption on breast cancer risk is controversial.
  • We examined the association between vegetable and fruit intake and breast cancer risk in a hospital-based case-control study conducted in Guangdong, China.
  • Total vegetable and fruit intake was found to be inversely associated with breast cancer risk.
  • Consumption of individual vegetable and fruit groups such as dark green leafy vegetables, cruciferous vegetables, carrots and tomatoes, banana, watermelon/papaya/cantaloupe were all inversely and significantly related with breast cancer risk.
  • These data indicate that greater intake of vegetables and fruits is associated with a decreased risk of breast cancer among Chinese women residing in Guangdong.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / prevention & control. Diet. Fruit. Vegetables
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / prevention & control. Adult. Aged. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / prevention & control. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / prevention & control. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / prevention & control. Carcinoma, Medullary / epidemiology. Carcinoma, Medullary / prevention & control. Case-Control Studies. Female. Humans. Middle Aged. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358284.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Park CS, Lee JH, Yim HW, Kang BJ, Kim HS, Jung JI, Jung NY, Kim SH: Observer agreement using the ACR Breast Imaging Reporting and Data System (BI-RADS)-ultrasound, First Edition (2003). Korean J Radiol; 2007 Sep-Oct;8(5):397-402
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Observer agreement using the ACR Breast Imaging Reporting and Data System (BI-RADS)-ultrasound, First Edition (2003).
  • OBJECTIVE: This study aims to evaluate the degree of inter- and intraobserver agreement when characterizing breast abnormalities using the Breast Imaging Reporting and Data System (BI-RADS)-ultrasound (US) lexicon, as defined by the American College of Radiology (ACR).
  • Static sonographic images of each breast lesion were acquired and reviewed by four radiologists with expertise in breast imaging.
  • CONCLUSION: Although BI-RADS-US was created to achieve a consensus among radiologists when describing breast abnormalities, our study shows substantial intraobserver agreement but only moderate interobserver agreement in the mass description and final assessment of breast abnormalities according to its use.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Ultrasonography, Mammary / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Roentgenol. 2001 Jul;36(3):217-25 [11475068.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Tumori. 1988 Jun 30;74(3):275-9 [3400118.001]
  • [Cites] APMIS. 1989 Aug;97(8):689-98 [2669853.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1054-8 [1627374.001]
  • [Cites] Radiology. 2006 May;239(2):385-91 [16569780.001]
  • [Cites] Radiology. 1995 Jul;196(1):123-34 [7784555.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):773-8 [8610547.001]
  • [Cites] Acta Radiol. 1997 Jul;38(4 Pt 1):497-502 [9240666.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jun;172(6):1621-5 [10350302.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1260-5 [15788607.001]
  • [Cites] N Engl J Med. 1994 Dec 1;331(22):1493-9 [7969300.001]
  • (PMID = 17923782.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2626814
  •  go-up   go-down


64. Reena RM, Mastura M, Siti-Aishah MA, Munirah MA, Norlia A, Naqiyah I, Rohaizak M, Sharifah NA: Minichromosome maintenance protein 2 is a reliable proliferative marker in breast carcinoma. Ann Diagn Pathol; 2008 Oct;12(5):340-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance protein 2 is a reliable proliferative marker in breast carcinoma.
  • This is a study aimed to examine the distribution pattern of a specific minichromosome maintenance protein 2 (MCM2) in benign and malignant breast tissue.
  • We used immunohistochemistry to examine the distribution and expression pattern of MCM2 on formalin-fixed paraffin-embedded tissue sections of benign (n = 30) and malignant breast tissue (n = 70) (IDC 56, DCIS 4, ILC 2, nonductal 4, mixed type 4).
  • Minichromosome maintenance protein 2 expression in breast cancer showed a positive association with histologic grade (P < .05).
  • In all the benign breast tissue examined, no proliferating compartments could be characterized.
  • Minichromosome maintenance protein 2 is a useful proliferative marker of breast carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / secondary. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Proliferation. Female. Humans. Lymph Nodes / pathology. Middle Aged. Minichromosome Maintenance Complex Component 2. Receptors, Estrogen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774496.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


65. Gatti G, Pruneri G, Gilardi D, Brenelli F, Bassani G, Luini A: Report on a case of pure cribriform carcinoma of the breast with internal mammary node metastasis: description of the case and review of the literature. Tumori; 2006 May-Jun;92(3):241-3
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cribriform carcinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report on a case of pure cribriform carcinoma of the breast with internal mammary node metastasis: description of the case and review of the literature.
  • AIMS AND BACKGROUND: Pure ductal invasive carcinoma of the breast is more frequently associated with lymphatic invasion, lymph node involvement and high malignant histological grade than combined forms of breast carcinoma.
  • PATIENTS AND METHODS: We report our experience of a case of pure cribriform carcinoma, associated with an intraductal cribriform component, in which the sentinel axillary nodes were negative, while nodal and perinodal metastasis was detected in one internal mammary lymph node.
  • [MeSH-major] Adenocarcinoma. Breast Neoplasms. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16869243.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 11
  •  go-up   go-down


66. Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y: Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells. Virchows Arch; 2010 Apr;456(4):403-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells.
  • In order to test this hypothesis, we examined the co-expression of CD173 and CD174 with stem cell markers CD44 and CD133 by flow cytometry analysis, immunocytochemistry, and immunohistochemistry on cell lines and tissue sections from breast cancer.
  • In three breast cancer cell lines, the percentage of CD173(+)/CD44(+) cells ranged from 17% to >60% and of CD174(+)/CD44(+) from 21% to 57%.
  • In breast cancer tissue sections from 15 patients, up to 50% of tumor cells simultaneously expressed CD173, CD174, and CD44 antigens.
  • Co-immunoprecipitation and sandwich ELISA experiments on breast cancer cell lines suggested that CD173 and CD174 are carried on the CD44 molecule.
  • The results show that in these tissues CD173 (H2) and CD174 (LeY) are associated with CD44 expression, suggesting that these carbohydrate antigens are markers of cancer-initiating cells or of early progenitors of breast carcinomas.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD44 / metabolism. Biomarkers, Tumor / metabolism. Blood Group Antigens / metabolism. Breast Neoplasms / immunology. Fucosyltransferases / metabolism
  • [MeSH-minor] Antigens, CD / metabolism. Carcinoma, Intraductal, Noninfiltrating / immunology. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Glycoproteins / metabolism. Humans. Hydroxytestosterones / pharmacology. Peptides / metabolism. Stem Cells / drug effects. Stem Cells / immunology. Stem Cells / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20300773.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / CD44 protein, human; 0 / Glycoproteins; 0 / Hydroxytestosterones; 0 / Peptides; 2141-17-5 / 4,17 beta-dihydroxy-4-androstene-3-one; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.65 / 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase
  •  go-up   go-down


67. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res; 2006 Oct 1;66(19):9509-18
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
  • Human breast cancer cells express the chemokine CXCL10 (IP-10) and also its receptor CXCR3.
  • In this study, we have investigated the role of Ras activation in the regulation of CXCL10 and its receptor splice variant CXCR3-B in two human breast cancer cell lines MDA-MB-435 and MCF-7.
  • Selective inhibition of CXCR3-B using siRNA resulted in an increase in CXCL10-mediated breast cancer cell proliferation through G(i) proteins and likely involving CXCR3-A.
  • Finally, we observed intense expression of CXCL10 and CXCR3 in association with human breast cancer in situ, indicating that these observations may be of pathophysiologic significance.
  • Together, these results suggest that activation of Ras plays a critical role in modulating the expression of both CXCL10 and CXCR3-B, which may have important consequences in the development of breast tumors through cancer cell proliferation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL74436; United States / PHS HHS / / DBU16011; United States / NIDDK NIH HHS / DK / DK64182; United States / NHLBI NIH HHS / HL / R01 HL074436; United States / NIDDK NIH HHS / DK / T32 DK007726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL10 protein, human; 0 / CXCR3 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / RNA, Small Interfering; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


68. Dragun AE, Harper JL, Jenrette JM, Sinha D, Cole DJ: Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up. Int J Radiat Oncol Biol Phys; 2007 Jun 01;68(2):354-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up.
  • PURPOSE: To identify the factors that predict for excellent cosmesis in patients who receive MammoSite breast brachytherapy (MBT).
  • METHODS AND MATERIALS: One hundred patients with Stage 0, I, or II adenocarcinoma of the breast underwent adjuvant therapy using MBT.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / radiotherapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17383829.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069222
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


69. Tafe LJ, Schwab MC, Lefferts JA, Wells WA, Tsongalis GJ: A validation study of a new molecular diagnostic assay: the Dartmouth-Hitchcock Medical Center experience with the GeneSearch BLN assay in breast sentinel lymph nodes. Exp Mol Pathol; 2010 Feb;88(1):1-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A validation study of a new molecular diagnostic assay: the Dartmouth-Hitchcock Medical Center experience with the GeneSearch BLN assay in breast sentinel lymph nodes.
  • We compared the recently FDA-approved Veridex GeneSearch Breast Lymph Node (BLN) Assay (Veridex, LLC; Warren, NJ), a real time reverse transcriptase-polymerase chain reaction assay that is designed to detect metastases >0.2 mm, with our standard lymph node processing.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast. Carcinoma, Intraductal, Noninfiltrating. Carcinoma, Lobular. Female. Hospitals, Teaching. Humans. Keratin-19 / genetics. Lymph Node Excision. Lymphatic Metastasis. Mammaglobin A. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Predictive Value of Tests. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Uteroglobin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19840784.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


70. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations. Cancer Invest; 2006 Mar;24(2):119-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle control related proteins (p53, p21, and Rb) and transforming growth factor beta (TGFbeta) in benign and carcinomatous (in situ and infiltrating) human breast: implications in malignant transformations.
  • A comparative study of the products of the cell cycle control genes p53 (mutated form), p21, Rb (nonphosphorylated and phosphorylated form) and TGFbeta was performed by immunohistochemistry and Western blot, in benign breast disorders and breast cancer (in situ and infiltrating tumors).
  • For the five proteins studied, the relative numbers of positively stained cells were higher in in situ carcinoma than in benign breast diseases.
  • In infiltrating breast tumors, the relative numbers of positively stained cells were even higher than in in situ tumors except for the percentage of pRb immunostained cells, which decreased slightly in infiltrative tumors.
  • Present results suggest that accumulation of mutated p53, cytoplasmic p21, and pRb in breast gland epithelium might be a crucial point in the development of in situ adenocarcinoma.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Cell Cycle Proteins / biosynthesis. Cell Transformation, Neoplastic / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537179.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Retinoblastoma Protein; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


71. Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF: Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J; 2008 Jul-Aug;14(4):335-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adenocarcinoma / pathology. Age Factors. Axilla. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537917.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


72. Brandt SM, Young GQ, Hoda SA: The "Rosen Triad": tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol; 2008 May;15(3):140-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the basis of our review of the literature and our own experience, until such time as the biologic explanation and clinical implication of this triad is further elucidated, we recommend that pathologists be aware of this triad and should proactively seek the other 2 lesions if any one of these elements of this triad is identified in any diagnostic breast tissue.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Hyperplasia. Mammary Glands, Human / pathology. Middle Aged. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434766.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


73. Obenauer S, Sohns C, Werner C, Grabbe E: Computer-aided detection in full-field digital mammography: detection in dependence of the BI-RADS categories. Breast J; 2006 Jan-Feb;12(1):16-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The object of this study was to determine the performance of a computer-aided detection system in full-field digital mammography (Senographe 2000D, General Electric, Buc, France) in detecting carcinomas in breasts in dependence of the initial Breast Imaging Reporting and Data System (BI-RADS) categories.
  • [MeSH-major] Breast Neoplasms / radiography. Mammography / standards. Radiographic Image Interpretation, Computer-Assisted / standards
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radiography. Adult. Aged. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / radiography. Carcinoma, Lobular / pathology. Carcinoma, Lobular / radiography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / radiography. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radiography. False Positive Reactions. Female. Hemangiosarcoma / pathology. Hemangiosarcoma / radiography. Humans. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409582.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Gadre SA, Perkins GH, Sahin AA, Sneige N, Deavers MT, Middleton LP: Neovascularization in mucinous ductal carcinoma in situ suggests an alternative pathway for invasion. Histopathology; 2008 Nov;53(5):545-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim was to characterize mucinous DCIS (mDCIS) of the breast and to describe, to our knowledge for the first time, neovascularization in mucin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / blood supply. Carcinoma, Intraductal, Noninfiltrating / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983463.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Mucins; 0 / Trans-Activators; 0 / Vascular Endothelial Growth Factor A; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


75. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO: High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol; 2007 Mar;31(3):417-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was undertaken to determine the morphologic features and frequency of putative precursor lesions involved in the development of some pure forms of special types and low grade breast carcinoma.
  • Our observations suggest that these lesions represent family members of low grade precursor, in situ and invasive neoplastic lesions of the breast.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / pathology. Epithelial Cells / pathology. Precancerous Conditions / pathology

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):7-21 [23959112.001]
  • (PMID = 17325484.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Receptors, Estrogen
  •  go-up   go-down


76. Liu YJ, Yan PS, Li J, Jia JF: Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer. World J Gastroenterol; 2005 Nov 14;11(42):6601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the relationship between the expression levels of nm23 mRNA, CD44s, and CD44v6, and oncogenesis, development and metastasis of human gastric adenocarcinoma, colorectal adenocarcinoma, intraductal carcinoma of breast, and lung cancer.
  • METHODS: Using tissue microarray by immuhistochemical (IHC) staining and in situ hybridization (ISH), we examined the expression levels of nm23 mRNA, CD44s, and CD44v6 in 62 specimens of human gastric adenocarcinoma and 62 specimens of colorectal adenocarcinoma; the expression of CD44s and CD44v6 in 120 specimens of intraductal carcinoma of breast and 20 specimens of normal breast tissue; the expression of nm23 mRNA in 72 specimens of human lung cancer and 23 specimens of normal tissue adjacent to cancer.
  • RESULTS: The expression of nm23 mRNA in the tissues of gastric and colorectal adenocarcinoma was not significantly different from that in the normal tissues adjacent to cancer (P>0.05), and was not associated with the invasion of tumor and the pathology grade of adenocarcinoma (P>0.05).
  • However, the expression of nm23 mRNA was correlated negatively to the lymph node metastasis of gastric and colorectal adenocarcinoma (r = -0.49, P<0.01; r = -4.93, P<0.01).
  • The expression of CD44s in the tissues of gastric and colorectal adenocarcinoma was significantly different from that in the normal tissues adjacent to cancer (P<0.05; P<0.01).
  • CD44v6 was expressed in the tissues of gastric and colorectal adenocarcinoma only, the expression of CD44v6 was significantly associated with the lymph node metastasis, invasion and pathological grade of the tumor (r = 0.47, P<0.01; r = 5.04, P<0.01).
  • CD44s and CD44v6 were expressed in intraductal carcinoma of breast, the expression of CD44s and CD44v6 was significantly associated with lymph node metastases and invasion (P<0.01).
  • However, neither of them was expressed in the normal breast tissue.
  • In addition, the expression of CD44v6 was closely related to the degree of cell differentiation of intraductal carcinoma of breast (c2 = 5.68, P<0.05).
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. NM23 Nucleoside Diphosphate Kinases. Neoplasm Metastasis. Nucleoside-Diphosphate Kinase. Protein Array Analysis. Stomach Neoplasms / genetics. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425351.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / RNA, Messenger; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  • [Other-IDs] NLM/ PMC4355751
  •  go-up   go-down


77. Zhong L: Magnetic resonance imaging in the detection of pancreatic neoplasms. J Dig Dis; 2007 Aug;8(3):128-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combined MRI features of a focal pancreatic mass, pancreatic duct dilatation and parenchymal atrophy are highly suggestive of a ductal adenocarcinoma.
  • Intraductal papillary mucinous tumors are the uncommon low-grade malignancy of the pancreatic duct.
  • The most frequent tumors to metastasize to the pancreas are cancers of the breast, lung, kidney and melanoma.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / pathology. Humans. Neoplasms, Cystic, Mucinous, and Serous / diagnosis. Neoplasms, Cystic, Mucinous, and Serous / pathology. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17650223.001).
  • [ISSN] 1751-2972
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 10
  •  go-up   go-down


78. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol; 2005 Sep;18(9):1193-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DeltaNp63 (DNp63) has become widely used, in particular, for distinguishing invasive carcinomas from noninvasive ducts by highlighting the myoepithelial or basal cells in the breast and prostate, respectively.
  • As the ductal and intraductal proliferations of this organ become better characterized, the need for markers to distinguish among these processes increases.
  • A total of 25 cases were non-neoplastic pancreata, 25 were pancreatic intraepithelial neoplasia (PanIN) of various grades, and 50 were examples of pancreatic ductal adenocarcinoma.
  • Among invasive carcinomas, it seems to be entirely specific for areas of squamous differentiation. (II) Those incidental microcysts seen in acinar lobules and lined by attenuated cells are also positive for DNp63, which suggests that they may be metaplastic in nature, and that they do not represent neoplastic cells. (III) Unlike the ducts of other exocrine organs, breast and prostate, there are no DNp63-expressing cells in the normal pancreatic ducts, and therefore, this marker cannot be used in distinguishing invasive carcinomas from the non-invasive ducts. (IV) No p63-expressing 'stem' cells are present in the pancreas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976814.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / PAR-02-068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


79. Rodd CD, Velchuru VR, Holly-Archer F, Clark A, Pereira JH: Randomized clinical trial comparing two mastectomy techniques. World J Surg; 2007 Jun;31(6):1164-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / surgery. Electrocoagulation / instrumentation. Hemostasis, Surgical / instrumentation. Mastectomy, Simple / instrumentation. Surgical Instruments
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Aged. Blood Loss, Surgical / prevention & control. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Drainage. Female. Hematoma / etiology. Humans. Length of Stay. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Sentinel Lymph Node Biopsy / instrumentation. Seroma / etiology. Single-Blind Method. Surgical Wound Infection / etiology. Wound Healing / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17417709.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Kunju LP, Ding Y, Kleer CG: Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions. Pathol Int; 2008 Oct;58(10):620-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.
  • The distinction between tubular carcinomas (TC) and invasive well-differentiated (grade 1) ductal carcinoma (IDC) is important given treatment and prognostic differences.
  • Studies have described a strong association between flat epithelial atypia (FEA) and TC.
  • The incidence of FEA associated with grade 1 IDC is not well established.
  • The aim of the present study was to assess morphology and intra-epithelial lesions between 14 TC and 18 grade 1 IDC matched for size.
  • Of 14 TC, eight (57%) had associated FEA, seven (50%) had micropapillary atypical ductal hyperplasia (ADH), three (21%) had low nuclear grade ductal carcinoma in situ (DCIS), and four (29%) had lobular neoplasia.
  • Notably, only two of 18 (11%) grade 1 IDC had associated FEA.
  • Three of 18 (16%) grade 1 IDC had ADH, two (11%) had lobular neoplasia, and seven (39%) had DCIS.
  • All tubular carcinomas were estrogen receptor (ER) positive and negative for Her-2/neu overexpression.
  • All grade 1 IDC were ER positive but 5% also overexpressed Her-2/neu.
  • Axillary lymph node metastasis was present in 11% of grade 1 IDC and absent in TC.
  • A strong association was found between TC, FEA, and micropapillary ADH, which may reflect a biological progression.
  • Despite matching for tumor size, grade 1 IDC have a higher incidence of lymph node metastasis and may have Her-2-neu overexpression compared to TC.

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801081.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / R01 CA125577; United States / NCI NIH HHS / CA / CA090876; United States / NCI NIH HHS / CA / CA107469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


81. Ma DF, Katoh R, Zhou H, Wang PY: Promoting effects of milk on the development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in rats. Acta Histochem Cytochem; 2007 May 12;40(2):61-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We classified the mammary tumors into three histological types: intraductal papilloma, fibroadenoma, and adenocarcinoma.
  • Although the percent of intraductal papilloma and fibroadenoma was almost same among the three groups, malignant tumor was found only in the milk and estrone sulfate groups.
  • In conclusion, our results indicate that milk as well as estrone sulfate promotes the development of DMBA-induced mammary tumors in rat and could be associated with the occurrence of adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Diet Assoc. 1999 Oct;99(10):1228-33 [10524386.001]
  • [Cites] J Am Diet Assoc. 1998 May;98(5):537-47 [9597026.001]
  • [Cites] CA Cancer J Clin. 1982 Sep-Oct;32(5):301-13 [6811109.001]
  • [Cites] Br J Cancer. 1984 Jun;49(6):723-9 [6547346.001]
  • [Cites] Pathol Annu. 1971;6:1-59 [4342307.001]
  • [Cites] Cancer Res. 1972 Jul;32(7):1404-15 [4337828.001]
  • [Cites] Cancer. 1986 Dec 1;58(11):2363-71 [3768832.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):112-37 [3302534.001]
  • [Cites] J Natl Cancer Inst. 1989 Feb 15;81(4):278-86 [2913325.001]
  • [Cites] J Dairy Res. 1989 Feb;56(1):17-26 [2703558.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2363-5 [16331633.001]
  • [Cites] Arch Intern Med. 1998 Jan 12;158(1):41-5 [9437377.001]
  • [Cites] Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43 [9316608.001]
  • [Cites] Biol Reprod. 1997 Sep;57(3):495-506 [9282982.001]
  • [Cites] Med Hypotheses. 1997 Jun;48(6):453-61 [9247884.001]
  • [Cites] Am J Clin Nutr. 1996 Mar;63(3 Suppl):437S-41S [8615337.001]
  • [Cites] Science. 1993 Jan 29;259(5095):618-21 [8430308.001]
  • [Cites] IARC Sci Publ. 1993;(121):1-806 [8258476.001]
  • [Cites] Fundam Appl Toxicol. 1994 Jul;23(1):44-52 [7958562.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):190-7 [7707406.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):187-200 [11149572.001]
  • [Cites] Breast Cancer Res Treat. 2001 Dec;70(3):171-83 [11804181.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1301-11 [12208895.001]
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):491-6 [15122580.001]
  • [Cites] Med Hypotheses. 2005;65(6):1028-37 [16125328.001]
  • (PMID = 17576434.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC1874511
  •  go-up   go-down


82. Böttger T, Terzic A, Müller M: [Laparoscopic pancreatic resection]. Zentralbl Chir; 2006 Aug;131(4):309-14
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous tumor of borderline type.
  • [MeSH-major] Adenoma / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17004190.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Bouté V, Goyat I, Denoux Y, Lacroix J, Marie B, Michels JJ: Are the criteria of Tabar and Dean still relevant to radial scar? Eur J Radiol; 2006 Nov;60(2):243-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We noticed an associated atypical epithelial hyperplasia in 28.5% of the cases, intraductal or lobular in situ carcinoma in 9% and/or a ductal invasive carcinoma in 2% of the cases.
  • [MeSH-major] Adenocarcinoma / pathology. Breast / pathology. Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962279.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


84. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R: PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene; 2006 May 11;25(20):2931-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Emerging data suggest that p21-activated kinase 1 (Pak1), a downstream signaling molecule of the small GTPases, growth factors, and lipid signaling, is upregulated or hyperactivated in human breast cancer.
  • Our results showed that in a transgenic mouse model, overexpression of catalytically active Pak1 leads to the development of malignant mammary tumors and to a variety of other breast lesions, including focal solid nodules, ductal hyperplasia, and mini-intraductal neoplasm and adenoma.
  • Finally, we found that consistent with a role in breast tumor progression, Pak1 expression and its nuclear accumulation was increased progressively during the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely used multistep polyoma-middle T-antigen transgenic mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331248.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 65746; United States / NCI NIH HHS / CA / CA 90970
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Estrogen Receptor alpha; 0 / Pak1 protein, mouse; 0 / Receptors, Progesterone; EC 2.7.1.- / Map2k1 protein, mouse; EC 2.7.1.- / Map2k2 protein, mouse; EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2
  •  go-up   go-down


85. Nguyen BD, Lidner TK: Intraductal papilloma of the breast: F-18 FDG PET demonstration. Clin Nucl Med; 2005 Jul;30(7):481-2
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papilloma of the breast: F-18 FDG PET demonstration.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Papilloma, Intraductal / pathology. Papilloma, Intraductal / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Aged. Female. Humans. Incidental Findings. Intestinal Neoplasms / radionuclide imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965323.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


86. Bernathova M, Zelger B, Deardon D, Bodner G: Sonographic findings of an intraductal mucinous carcinoma. J Ultrasound Med; 2006 Jul;25(7):925-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic findings of an intraductal mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / ultrasonography. Breast Neoplasms / ultrasonography. Carcinoma, Intraductal, Noninfiltrating / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798906.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Sakamoto G: [Breast neoplasms: histological classification]. Nihon Rinsho; 2007 Jun 28;65 Suppl 6:54-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast neoplasms: histological classification].
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Scirrhous / pathology. Breast Neoplasms / classification. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682139.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


88. Muradali D, Kulkarni S: Sonography of the breast: to core or not to core? Can Assoc Radiol J; 2005 Dec;56(5):276-88
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography of the breast: to core or not to core?
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary
  • [MeSH-minor] Adenocarcinoma, Mucinous / ultrasonography. Algorithms. Artifacts. Biopsy. Breast Diseases / ultrasonography. Carcinoma, Ductal, Breast / ultrasonography. Carcinoma, Papillary / ultrasonography. Diagnosis, Differential. Fibroadenoma / ultrasonography. Hamartoma / ultrasonography. Humans. Lipoma / ultrasonography. Lymphatic Metastasis / ultrasonography. Lymphoma / ultrasonography. Magnetic Resonance Imaging. Neoplasm Metastasis / ultrasonography. Papilloma, Intraductal / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16579021.001).
  • [ISSN] 0846-5371
  • [Journal-full-title] Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes
  • [ISO-abbreviation] Can Assoc Radiol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


89. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH: Somatic mutation of pro-apoptosis caspase-6 gene is rare in breast and lung carcinomas. Pathology; 2006 Aug;38(4):358-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutation of pro-apoptosis caspase-6 gene is rare in breast and lung carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Apoptosis / genetics. Breast Neoplasms / genetics. Carcinoma, Intraductal, Noninfiltrating / genetics. Caspases / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916729.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.4.22.- / CASP6 protein, human; EC 3.4.22.- / Caspase 6; EC 3.4.22.- / Caspases
  •  go-up   go-down


90. Wagner TD, Wharton K, Donohue K, Sperl ML, Flaherty L, Jaggernauth W, Yap JC, Fernando SA, Landry JC, Yang GY: Pure tubular breast carcinoma: a 34 year study of outcomes. Breast J; 2008 Sep-Oct;14(5):512-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure tubular breast carcinoma: a 34 year study of outcomes.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Breast Neoplasms / epidemiology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Aged. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / therapy. Chemotherapy, Adjuvant. Female. Humans. Immunohistochemistry. Incidence. Mastectomy, Segmental / methods. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18821938.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


91. Manfrin E, Mariotto R, Remo A, Reghellin D, Dalfior D, Falsirollo F, Bonetti F: Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004). Cancer; 2008 Apr 25;114(2):74-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there still a role for fine-needle aspiration cytology in breast cancer screening? Experience of the Verona Mammographic Breast Cancer Screening Program with real-time integrated radiopathologic activity (1999-2004).
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2008 Apr 25;114(2):65-6 [18327791.001]
  • (PMID = 18306357.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Narimatsu H: [High-resolution MR mammography: MR features and technique]. Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Nov 20;61(11):1475-85
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Female. Fibroadenoma / diagnosis. Humans. Papilloma, Intraductal / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16317406.001).
  • [ISSN] 0369-4305
  • [Journal-full-title] Nihon Hōshasen Gijutsu Gakkai zasshi
  • [ISO-abbreviation] Nihon Hoshasen Gijutsu Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Soesan M, de Snoo F, Westerga J, Floore A, Bender R: Microarray analysis as a helpful tool in identifying the primary tumour in cancer with an unknown primary site. Neth J Med; 2010 Jan;68(1):50-1
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / diagnosis. Gene Expression Profiling. Neoplasms, Unknown Primary / diagnosis. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Humans. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20103826.001).
  • [ISSN] 1872-9061
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


94. MacGrogan G: [Diagnostic pitfalls in mammary pathology. Case 1. In situ ductal carcinoma of low nuclear grade, with papillary, micropapillary and cribriform architecture]. Ann Pathol; 2009 Jun;29(3):188-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Neoplasms, Multiple Primary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Cell Nucleus / ultrastructure. Diagnosis, Differential. Female. Humans. Hyperplasia. Keratins / analysis. Membrane Proteins / analysis. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619824.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


95. Pelosi G, Sonzogni A, Rosai J: Thyroid-type papillary microcarcinoma in ovarian strumal carcinoid. Int J Surg Pathol; 2008 Oct;16(4):435-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Carcinoid Tumor / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology
  • [MeSH-minor] Aged. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480390.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement